{"id":"W2192572578","doi":"10.1158/1078-0432.ccr-15-1681","title":"A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Bayer HealthCare","keywords":"Sorafenib; Pharmacokinetics; Medicine; Tolerability; Pharmacodynamics; Dosing; Pharmacology; Internal medicine; Hepatocellular carcinoma; Adverse effect; Cancer; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001002674,0.0001105164,0.0002528451,0.00005194868,0.00003904504,0.000006256302,0.0002483334,0.00006779839,0.000009132166],"category_scores_gemma":[0.0001034216,0.00006718213,0.00002626142,0.0002718746,0.0003428429,0.000006359029,0.0001487783,0.0002712519,1.389832e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004077443,"about_ca_system_score_gemma":0.0004622253,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003012909,"about_ca_topic_score_gemma":0.0005692803,"domain_scores_codex":[0.9981512,0.0004543601,0.0003823733,0.0003236355,0.0004819706,0.0002064496],"domain_scores_gemma":[0.9986737,0.00006969571,0.0001709022,0.0002947808,0.0006870539,0.0001039072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0412706,0.007137004,0.8709027,0.00006753285,0.0002024965,0.000003004715,0.0007313975,0.0005518325,0.01534359,0.00002313164,0.0002568461,0.0635099],"study_design_scores_gemma":[0.2745878,0.06754845,0.5705324,0.0002896227,0.0001035194,0.000001070923,0.001495694,0.001192881,0.07625633,0.00007797092,0.007362084,0.0005521655],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977988,0.0006334331,0.00001234117,0.0001246732,0.0001087443,0.001154107,0.00005882438,0.000002336004,0.0001067251],"genre_scores_gemma":[0.9984121,0.00123629,0.00003534758,0.00004506826,0.00004831623,0.0001124422,0.00001759796,0.00001868651,0.00007420722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3003702,"threshold_uncertainty_score":0.2739608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180769002499015,"score_gpt":0.4794947159108082,"score_spread":0.3614178156609067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}